Andrew Baum, MD
Head of Global Healthcare; Managing Director, Equity Research
Citi
Andrew Baum, MD, joined Citi in September 2011, as the Global Head of Healthcare Research. He benefits from a deep strategic insight of the global healthcare value chain, as well as broad network of contacts throughout the industry. In 2004, Dr Baum was one of the earliest commentators to highlight to investors the deep structural deficiencies of the historic operating structure and the need to evolve towards a radically different model.Dr Baum is widely sought after to share his insights with the most senior levels of management within the healthcare industry. He regularly lectures for a number of prestigious organisations including The Institute of Comparative Law, The World Vaccine Congress as well as occasional presentations to some of the leading management consultancies.Before joining the firm, Dr Baum was at Morgan Stanley 14-years, where he was the top ranked European Pharmaceutical Analyst in the Extel Poll for six years. Dr Baum and his team consistently ranked in the top three teams in external EU and Global investor polls (Institutional Investor, Greenwich and Reuters). Before this, Dr Baum was a UK pharmaceutical and biotechnology analyst at Salomon Brothers. From 1994 to 1996, he was a practicing physician at the Royal National Orthopaedic Radcliffe Hospital in Oxford (the medical centre of Oxford University) where he completed his residency. Dr Baum is a member of the American Heart Association, American Society of Oncology and the DIA. He is also a Fellow of the Royal Society of Medicine. Dr Baum holds an MA in Physiological Sciences and an MD from Oxford University.
